<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Poordad, Fred</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Sustained Virologic Response of 91% in Patients Infected with HCV Treated with DCV-TRIO</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">Daclatasvir is a pangenotypic (genotypes [GT] 1–6 in vitro and GT 1–4 in clinical trials) NS5A inhibitor with a low potential for drug-drug interactions. It is approved in Europe and Japan, and it is under regulatory review in the United States. The aim of the phase 3 UNITY-1 trial [NCT01979939] was to evaluate this all-oral, ribavirin-free combination in noncirrhotic treatment-naïve and treatment-experienced patients with hepatitis C virus (HCV) genotype (GT) 1 infection.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>